Skip to main content

Advertisement

SpringerLink
Log in

Adjuvant Endocrine Therapy for the Surgeon: Options, Side Effects, and their Management

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Adjuvant endocrine therapy is often advised for women with hormone receptor positive breast cancer. In premenopausal women, tamoxifen is the primary endocrine therapy option since aromatase inhibitors (AIs) are contraindicated in patients with residual ovarian function. The benefit of ovarian ablation/suppression in premenopausal patients remains controversial. In postmenopausal ER positive patients, treatment with an AI alone, switching strategies with an AI and tamoxifen, or extended therapy with an AI after 5 years of tamoxifen are superior to 5 years of tamoxifen alone. While the data supporting the use of endocrine therapy for ER positive breast cancer is clear, adverse effects occur with variable frequency and severity. The intensity and severity of the most common endocrine therapy adverse effects are mild to moderate for the majority of women, and serious life-threatening adverse effects are uncommon. However, compliance issues are often larger than recognized. Good communication with patients is critical to address concerns and symptoms, and more research is needed to identify effective methods to minimize treatment side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fabian CJ. The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. Int J Clin Pract. 2007;61(12):2051–63.

    Article  PubMed  CAS  Google Scholar 

  2. International Breast Cancer Study Group. Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12–93 and 14–93. Ann Oncol. 2004;15:1749–59.

    Article  Google Scholar 

  3. Fisher B, Jeong J-H, Dignam J, Anderson S, Mamounas E, Wickerham DL, Wolmark N. Findings from recent national surgical adjuvant breast and bowel project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr. 2001;30:62–6.

    Article  PubMed  Google Scholar 

  4. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011; 378: 771–84.

    Google Scholar 

  5. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-717.

    Article  Google Scholar 

  6. Davies C, Pan H, Godwin J et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–16.

    Article  PubMed  CAS  Google Scholar 

  7. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases. Lancet. 1896;II(104–7):162–5.

    Article  Google Scholar 

  8. Griggs J, Somerfield M, Anderson H, et al. American Society of Clinical Oncology endorsement of the cancer care ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer. J Clin Oncol. 2011;29(29):3939–42.

    Article  PubMed  Google Scholar 

  9. LHRH-agonists in Early Breast Cancer Overview group. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007;360:1711–23.

    Google Scholar 

  10. Swain S, Jeong J-H, Geyer C, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010; 362(22):2053–65.

    Article  PubMed  CAS  Google Scholar 

  11. Goss P, Ingle J, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349(19):1793–802.

    Article  PubMed  CAS  Google Scholar 

  12. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF; ATAC/LATTE investigator. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135–41.

    Article  PubMed  CAS  Google Scholar 

  13. The Breast International Group (BIG) 1–98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747–57.

    Article  Google Scholar 

  14. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366:455–62.

    Article  PubMed  CAS  Google Scholar 

  15. van de Velde C, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet. 2011;377:321–31.

    Article  PubMed  Google Scholar 

  16. The BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361(8):766–76.

    Article  Google Scholar 

  17. Higgins M, Liedke P, Goss P. Extended adjuvant endocrine therapy in hormone dependent breast cancer: The paradigm of the NCIC-CTG MA.17/BIG 1–97 trial. Crit Rev Oncol Hematol. 2013;86:23–32.

    Article  PubMed  Google Scholar 

  18. Goss P. National Cancer Institute of Canada Clinical Trials Group MA-27 trial reported at the San Antonio Breast Cancer Symposium, December 2012.

  19. Fontein DBY, Seynaeve C, Hadji P, et al. Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial Analysis. J Clin Oncol. 2013 31(18):2257–64. doi:10.1200/JCO.2012.45.3068.

    Article  PubMed  CAS  Google Scholar 

  20. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology Practice Guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010;28:3784–96.

    Article  PubMed  Google Scholar 

  21. Fallowfield LJ, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life in postmenopausal women in the arimidex, tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial. J Clin Oncol. 2004;22:4261–71.

    Article  PubMed  CAS  Google Scholar 

  22. Fallowfield LJ, Kilburn LS, Langridge C, Snowdon CF, Bliss JM, Coombes RC on behalf of the IES Trial Steering Committee. Long-term assessment of quality of life in the intergroup exemestane study: 5 years post-randomisation. Br J Cancer. 2012;106:1062–7.

    Article  PubMed  CAS  Google Scholar 

  23. Garreau JR, DeLaMelena T, Walts D, Karamlou K, Johnson N. Side effects of aromatase inhibitors versus tamoxifen: the patients’ perspective. Am J Surg. 2006;192:496–8.

    Article  PubMed  CAS  Google Scholar 

  24. Blaha P, Exner R, DalBorgo A, et al. Is endocrine therapy really pleasant? considerations about the long-term use of antihormonal therapy and its benefit/side effect ratio. Breast Care. 2009;4:155–61.

    Article  PubMed  Google Scholar 

  25. Hershman DL, Kushi L, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28:4120–8.

    Article  PubMed  Google Scholar 

  26. Aiello Bowles EJ, Boudreau DM, Chubak J, Yu O, Fujii M, Chestnut J, Buist DSM. Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J Oncol Pract. 2012;8:e149–57.

    Article  PubMed  Google Scholar 

  27. Friese C, Pini TM, Li Y, et al. Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer. Breast Cancer Res Treat. 2013;138:931–9.

    Article  PubMed  CAS  Google Scholar 

  28. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999;91:1829–46.

    Article  PubMed  CAS  Google Scholar 

  29. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320:479–84.

    Article  PubMed  CAS  Google Scholar 

  30. Mouridsen HT. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women. Curr Med Res Opin. 2006;22:1609-21.

    Article  PubMed  CAS  Google Scholar 

  31. Cella D, Fallowfield LJ. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2008;107:167–80.

    Article  PubMed  CAS  Google Scholar 

  32. Michaëllson K, Melhus H, Warensjö Lemming E, Wolk A, Byberg L. Long-term calcium intake and rates of all cause and cardiovascular mortality: community-based prospective longitudinal cohort study. BMJ. 2013;346:f228.

    Article  Google Scholar 

  33. Greenlee H, Crew KD, Shao T, et al. Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer. Support Care Cancer. 2013;21:1077-87.

    Article  PubMed  Google Scholar 

  34. Crew KD, Capodice JL, Greenlee H, et al. Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J Clin Oncol. 2010;28:1154–60.

    Article  PubMed  CAS  Google Scholar 

  35. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen at 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a Randomised Trial. Lancet 2013;381:805–16.

    Article  PubMed  CAS  Google Scholar 

  36. Breast Cancer Social Media Community http://www.bcsmcommunity.org.

  37. Walker EM, Rodriguez AI, Kohn B, et al. Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J Clin Oncol. 2010;28:638–40.

    Google Scholar 

  38. Hind D, Wyld L, Beverley C, Reed M. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Libr. 2008, 3.

  39. Hughes K, Schnaper L, Bellon J, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31:2382-7.

    Article  PubMed  CAS  Google Scholar 

  40. NCCN Guidelines. Breast Cancer. Version 3.2013.

  41. Pemmaraju N, Munsell MF, Hortobagyi GN, Giordano SH. Retrospective review of male breast cancer patients: analysis of tamoxifen-related side effects. Ann Oncol. 2011. doi: 10.1093/annonc/mdr459.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. General Surgery, University of Kansas Medical Center, Kansas, KS, USA

    Carol Connor

  2. Center For Breast Care, Inc, Burbank, CA, USA

    Deanna Attai

Authors
  1. Carol Connor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deanna Attai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carol Connor.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Connor, C., Attai, D. Adjuvant Endocrine Therapy for the Surgeon: Options, Side Effects, and their Management. Ann Surg Oncol 20, 3188–3193 (2013). https://doi.org/10.1245/s10434-013-3177-1

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-013-3177-1

Keywords

Search

Navigation